Year-end Sale % OFF 
Abstract
ALK+ anaplastic large cell lymphoma (ALCL) is a mature T-cell lymphoma with NPM1::ALK fusion or a variant ALK rearrangement. Immunophenotyping including ALK, morphology, and clinical studies including imaging, are generally considered adequate for diagnosis. While specific ALK fusion partners do not appear to have prognostic significance, they may influence the efficacy of ALK inhibitor therapies. We report a case of an 18-year-old male with a right cranio-orbital bone mass. The CD30/CD4/CD45 positive pleomorphic neoplastic cells expressed diffuse cytoplasmic ALK, overall consistent with an ALK+ ALCL, most likely with non-NPM1 partner.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
